IGC Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -416.75% compared to IGC Pharma's net margin of --. IGC Pharma's return on equity of -137.43% beat CEL-SCI's return on equity of --.

IGC Pharma has a consensus price target of $3.63, signalling upside risk potential of 1031.73%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 2010.63%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

IGC Pharma has a beta of 1.325, which suggesting that the stock is 32.462% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $412K, which are larger than CEL-SCI quarterly revenues of --. IGC Pharma's net income of -$1.7M is higher than CEL-SCI's net income of -$6.9M. Notably, IGC Pharma's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.38x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -416.75% compared to IGC Pharma's net margin of -49.65%. IGC Pharma's return on equity of -137.43% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

IGC Pharma has a consensus price target of $3.63, signalling upside risk potential of 1031.73%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 483.4%. Given that IGC Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe IGC Pharma is more attractive than NovaBay Pharmaceuticals.

IGC Pharma has a beta of 1.325, which suggesting that the stock is 32.462% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $412K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGC Pharma's net income of -$1.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, IGC Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.38x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -416.75% compared to IGC Pharma's net margin of 18.02%. IGC Pharma's return on equity of -137.43% beat Protalix BioTherapeutics's return on equity of -29.54%.

IGC Pharma has a consensus price target of $3.63, signalling upside risk potential of 1031.73%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 516.74%. Given that IGC Pharma has higher upside potential than Protalix BioTherapeutics, analysts believe IGC Pharma is more attractive than Protalix BioTherapeutics.

IGC Pharma has a beta of 1.325, which suggesting that the stock is 32.462% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.881%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $412K, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. IGC Pharma's net income of -$1.7M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, IGC Pharma's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.38x versus 3.90x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -416.75% compared to IGC Pharma's net margin of -2357.27%. IGC Pharma's return on equity of -137.43% beat Palatin Technologies's return on equity of --.

IGC Pharma has a consensus price target of $3.63, signalling upside risk potential of 1031.73%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1316.67%. Given that Palatin Technologies has higher upside potential than IGC Pharma, analysts believe Palatin Technologies is more attractive than IGC Pharma.

IGC Pharma has a beta of 1.325, which suggesting that the stock is 32.462% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $412K, which are larger than Palatin Technologies quarterly revenues of $350K. IGC Pharma's net income of -$1.7M is higher than Palatin Technologies's net income of -$7.8M. Notably, IGC Pharma's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.38x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.